Pharmacy Times

PRODUCT news


Amoxicillin and Clavulanate Potassium for Oral Suspension


Marketed by:
Sandoz Inc (Princeton, NJ)

Compared to:
Augmentin ES-600 (GlaxoSmithKline)

Indication:
October 1, 2007—Sandoz Inc introduced an extension of its line of amoxicillin and clavulanate potassium for oral suspension. This newest addition is being marketed in 600-mg/42.9-mg-per-5-mL strength. In addition, the company markets amoxicillin and clavulanate potassium in tablets and in chewable tablets. Amoxicillin and clavulanate potassium is used to treat bacterial infections.

Dosage Form:
Oral suspension: 600 mg/42.9 mg per 5 mL, 200 mg/28.5 mg per 5 mL, and 400 mg/57 mg per 5 mL; Tablets: 250 mg/125 mg, 500 mg/125 mg, and 875 mg/125 mg; Chewable tablets: 200 mg/28.5 mg and 400 mg/57 mg

For More Information:
www.us.sandoz.com


Ciclopirox Topical Solution, 8% (Nail Lacquer)


Marketed by:
Teva Pharmaceuticals (North Wales, Pa)

Compared to:
Penlac Nail Lacquer (Aventis Pharmaceuticals Inc)

Indication:
September 19, 2007—Teva Pharmaceuticals announced the introduction and availability of Ciclopirox Topical Solution, 8% (Nail Lacquer). As a component of a comprehensive management program, this product is indicated as topical treatment in immunocompetent patients with mild-to-moderate onychomycosis of the fingernails and toenails without lunula involvement, due to Trichophyton rubrum. The comprehensive management program also includes removal of the unattached, infected nails as frequently as monthly by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures.

Dosage Form:
6.6-mL glass bottles

For More Information:
www.tevausa.com


Hydrocodone Bitartrate and Acetaminophen Tablets USP


Marketed by:
Ranbaxy Pharmaceuticals Inc (Jacksonville, Fla)

Compared to:
Vicodin ES Tablets (Abbott Laboratories); Norco Tablets (Watson Pharmaceuticals Inc); Lortab Tablets (UCB Inc)

Indication:
August 20, 2007—Ranbaxy Pharmaceuticals Inc, a wholly owned subsidiary of Ranbaxy Laboratories Ltd (RLL), announced that RLL received FDA approval to manufacture and market Hydrocodone Bitartrate and Acetaminophen Tablets USP, 7.5-mg/750-mg, 10- mg/500-mg, 5-mg/500-mg, and 10-mg/325-mg strengths. The Office of Generic Drugs, US FDA, has determined the Ranbaxy formulations to be bioequivalent and to have the same therapeutic effect as that of the reference listed drugs as follows: 10-mg/325- mg Norco Tablets from Watson Pharmaceuticals Inc; 5-mg/500-mg Vicodin Tablets and 7.5-mg/750-mg Vicodin ES Tablets, both from Abbott Laboratories; and 10-mg/500-mg Lortab Tablets from UCB Inc. These tablets are indicated for the relief of moderate-tomoderately severe pain.

Dosage Form:
Tablets: 7.5 mg/750 mg, 10 mg/500 mg, 5 mg/500 mg, and 10 mg/325 mg

For More Information:
www.ranbaxyusa.com


Quinapril Tablets


Marketed by:
Teva Pharmaceuticals (North Wales, Pa)

Compared to:
Accupril Tablets (Warner-Lambert Co)

Indication:
October 3, 2007—Teva Pharmaceuticals announced the introduction and availability of Quinapril Tablets USP. They are indicated for the treatment of hypertension and may be used alone or in combination with thiazide diuretics. Black patients receiving angiotensin-converting enzyme (ACE) inhibitor monotherapy have been reported to have a higher incidence of angioedema, compared with nonblacks. It also should be noted that, in controlled clinical trials, ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks.

Dosage Form:
Tablets: 5, 10, 20, and 40 mg

For More Information:
www.tevausa.com